请选择 进入手机版 | 继续访问电脑版
设为首页收藏本站

老西部英语

 找回密码
 立即注册

只需一步,快速开始

[大学生论坛]:科学家发现治疗肾移植后慢性排斥反应新靶点

15

主题

15

资源

62

积分

注册会员

Rank: 2

积分
62
zyf950201 发表于 2017-12-31 16:56:22 | 显示全部楼层 |阅读模式
中外科学家团队最近发现治疗肾移植后慢性排斥反应的新靶点——选择性的免疫蛋白酶体,这项成果对于保护移植肾脏功能具有积极作用。
A team of Chinese and foreign scientists recently discovered a new target for chronic rejection treatment after kidney transplantation - selective immunoproteinase, which has a positive effect on the protection of transplanted kidney’s function.
这项由重庆市肿瘤医院泌尿外科副主任李俊博士联合德国科学家发表的研究成果,名为“抑制免疫蛋白酶体防治抗体介导的慢性肾移植排斥”,以重庆市肿瘤医院为第一及通讯作者单位,近期在国际泌尿及肾病领域顶级学术期刊《国际肾脏病》在线发表。
This study, named Supress Immunoproteinase to Prevent and Treat  Antibody Mediated Chronic Kidney Transplantation Rejection, is done by Dr Li Jun(director of urology at the chongqing cancer hospital) and German scientist. Recently, it was published online on the top academic journal in the field of international urology and nephropathy, International Kidney Disease, taking the tumor hospital as the first and the corresponding author.
李俊介绍,在临床实践中,患者在接受肾移植后的10年内,由于抗移植肾抗体的产生,大约有50%会发生慢性排斥反应,导致移植肾功能降低甚至无功能,需要再次移植。
According to Li Jun, in the clinical practice, in 10 years after receiving the kidney transplantation, due to the production of anti-transplantation kidney antibodies, about 50% of the patients will have chronic rejection, which leads to the reduction of the transplanted kidney’s function and even lose function, and they need to be transplanted again.
“虽然有实验表明,非选择性的蛋白酶体抑制剂可以抑制抗体介导的移植排斥反应,但其副作用广泛,难以在临床应用。”李俊说,目前,对于由抗体介导的慢性排斥反应仍缺乏有效治疗手段。
"Although experiments have shown that non-selective protease inhibitors can supress the antibody mediated transplantion rejection, its side effects are widespread and it’s difficult to be applied clinically." Currently, there is still a lack of effective treatment for chronic antibodies mediated rejection, Li said.
在李俊主导完成的大鼠肾移植模型中,发现了选择性抑制免疫蛋白酶体,可减少移植受体内产生抗体细胞的数量,减轻移植肾损害,保护肾功能。李俊介绍,选择性的免疫蛋白酶体抑制,在实验中不仅显示出良好的疗效,且几乎未见副作用。
In kidney transplantation model of rats, which is completed by Li , discovered that the selective inhibition of immune proteasome can reduce the production of antibodies in transplanted body,  lighten the damage of transplanted kidney, protect kidney’s function. According to Li, the selective immunoproteinase suppression showed not only good efficacy but also caused almost no side effects in the experiment.
该项研究成果是肾移植领域的一大进步,提示选择性的免疫蛋白酶体可能是防治肾移植后慢性排斥反应极具潜力的新靶点,其抑制剂的开发、应用为保护患者移植肾功能,延长肾移植患者生存带来了希望。
This research is a big progress in the field of kidney transplantation, prompts that selective immune proteasome may be the most protential new target to prevent and treat chronic rejection after kidney transplantation, the development, application of inhibitors brings the hope to protect the patients’ transplated kidney and prolong patients’s survival rate.

来源:健康报医学前沿,源自新华网。http://www.jkb.com.cn/medicalFrontier/2017/1219/423056.html
日期:2017-12-19

2014级商务英语 张远峰 3141204012





友荐云推荐
评论

使用道具 举报


QQ|关于我们|联系我们|网络条款|建议反馈|小黑屋|老西部英语 ( 版权所有 粤ICP备11103350号  

GMT+8, 2018-6-24 03:28 , Processed in 0.140933 second(s), 34 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.